A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor
- 4 July 2011
- journal article
- clinical trial
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 47 (4), 483-487
- https://doi.org/10.1038/bmt.2011.133
Abstract
Autologous hematopoietic stem cell (HSC) transplant is an effective treatment for patients with hematological malignancies. Unfortunately, 15-30% of patients fail to mobilize a sufficient number of HSCs for the transplant. Plerixafor is now used as a salvage mobilization regimen, with good success. We describe here a risk-based approach for the use of plerixafor, based on the circulating CD34(+) cell count and the CD34(+) cell dose collected after 4 days of G-CSF, that identifies potential poor HSC mobilizers upfront. A total of 159 patients underwent HSC collections using this approach. Of these, 55 (35%) were identified as high risk owing to low CD34(+) cell number or low yield on day 1 of collection, and received plerixafor on the subsequent days of collection. Of the 159 patients, 151 (95%) were able to provide adequate collections with the first mobilization attempt in a median of 1.7 days using this approach. Of the eight who failed initial mobilization, 5 successfully underwent re-mobilization with plerixafor and G-CSF and 3 (1.9%) were mobilization failures. This approach helped to control the overall cost of HSC collections for our BMT program by decreasing the need for remobilization, reducing the number of collection days and avoiding the use of plerixafor in all patients.Keywords
This publication has 17 references indexed in Scilit:
- Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and CyclophosphamideTransplantation and Cellular Therapy, 2010
- Preharvest hematopoietic progenitor cell counts predict CD34+ cell yields in granulocyte–colony‐stimulating factor–mobilized peripheral blood stem cell harvest in healthy donorsTransfusion, 2010
- Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilizationBone Marrow Transplantation, 2010
- Poor Mobilization of Hematopoietic Stem Cells—Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous TransplantationTransplantation and Cellular Therapy, 2009
- Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myelomaBlood, 2009
- AMD3100 Is a CXCR7 Ligand with Allosteric Agonist PropertiesMolecular Pharmacology, 2009
- Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonistThe Journal of Experimental Medicine, 2005
- Mobilization of CD34+ cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimenBritish Journal of Haematology, 2003
- Current understanding of stem cell mobilizationExperimental Hematology, 2002
- The ISHAGE Guidelines for CD34+ Cell Determination by Flow CytometryJournal of Hematotherapy, 1996